Trial Profile
An open label post marketing surveillance assessment to evaulate the effectiveness and safety of Rapamune [sirolimus] in patients after kidney transplantation receiving a Rapamune containing regime
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Mar 2008
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Wyeth
- 13 Mar 2008 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 21 Dec 2007 Status changed from recruiting to suspended.
- 31 May 2007 Status changed from in progress to recruiting.